Pharmacologic management of neuropsychiatric lupus
Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2016
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24044
- Acceso en línea:
- https://doi.org/10.1586/17512433.2016.1111137
https://repository.urosario.edu.co/handle/10336/24044
- Palabra clave:
- Antimalarial agent
Azathioprine
Belimumab
Blood group b antibody
Chloroquine
Cyclophosphamide
Glucocorticoid
Hydroxychloroquine
Immunoglobulin
Methylprednisolone
Methylprednisolone sodium succinate
Mycophenolate mofetil
Prednisone
Rituximab
Anticonvulsive agent
Antidepressant agent
Cyclophosphamide
Glucocorticoid
Immunosuppressive agent
Anticoagulation
Computer assisted tomography
Human
Immunosuppressive treatment
Lupus erythematosus nephritis
Lupus vulgaris
Neuropsychiatric lupus
Nuclear magnetic resonance imaging
Nuclear magnetic resonance spectroscopy
Palliative therapy
Pharmaceutical care
Phase 3 clinical trial (topic)
Plasmapheresis
Positron emission tomography
Randomized controlled trial (topic)
Review
Single photon emission computer tomography
Systematic review (topic)
Systemic lupus erythematosus
Animal
B lymphocyte
Complication
Immunology
Pathophysiology
Procedures
Animals
Anticonvulsants
Antidepressive agents
B-lymphocytes
Cyclophosphamide
Glucocorticoids
Humans
Immunosuppressive agents
Plasmapheresis
Anti-ribosomal p antibodies
Cyclophosphamide
Depression
Neuropsychiatric lupus
Systemic lupus erythematosus
central nervous system
central nervous system
systemic
Lupus vasculitis
Lupus erythematosus
Lupus vasculitis
- Rights
- License
- Abierto (Texto Completo)